Merck (NYSE:MRK), known as MSD outside the United States and Canada, and Hanwha Chemical Corporation (KOSPI: 09830) today announced that they have ent ...

Merck has launched a sweeping cost-cutting effort designed to save $3 billion annually by the end of 2027, the company said ...

Global pharmaceutical company Merck (NYSE:MRK) in Q2 CY2025, but sales fell by 1.9% year on year to $15.81 billion. The ...

Facing patent expiration for its blockbuster Keytruda, Merck aims to streamline operations with significant job cuts and ...

Merck has characterized its cost-cutting initiative as more of a reallocation of resources to support other, higher-growth ...

Facing an end to Keytruda's market exclusivity, the company will cut $3 billion in costs that it plans to redeploy in support ...

Drug maker Merck announced Tuesday it will embark on an initiative to cut $3 billion in costs 2027, including an undisclosed ...

The multiyear effort comes as Merck prepares to offset revenue losses from the upcoming patent expiration of its blockbuster ...

Merck & Co., Inc. (NYSE:MRK) is one of the most undervalued blue chip stocks to buy according to hedge funds. On July 21, ...

Carol Ferguson, 908-423-4465 or Hanwha Chemical Corp: Media: HyukBum Kwon, +82-2-729-3127 or Investor: JaeHong Jeon, +82-2-729-4016 KEYWORDS: United States Asia Pacific North America New Jersey ...